-
公开(公告)号：US20130031871A1
公开(公告)日：2013-02-07
申请号：US13565567
申请日：2012-08-02
申请人： John Helmsderfer , Alex Androski , Andrew Ahr , Thomas Coulter , Kyle Ridlon , Nicholas Jeffers
发明人： John Helmsderfer , Alex Androski , Andrew Ahr , Thomas Coulter , Kyle Ridlon , Nicholas Jeffers
CPC分类号： B65B31/048
摘要： A vacuum apparatus for sealing an airtight bag includes a tongue in fluid communication with a vacuum chamber and base members that close around and seal a section of the bag. The once closed, the apparatus facilitates fluid communication between the interior of the airtight bag and the vacuum chamber, allowing actuation of the vacuum chamber to result in evacuation of air from the bag. The tongue may take the form of a removable tube device or may be designed to puncture the bag. The apparatus may be wholly removable after evacuation of the bag, or some part of the apparatus may remain on the bag in order to maintain the airtight seal.
摘要翻译： 用于密封气密袋的真空装置包括与真空室流体连通的舌片和围绕并密封袋的一部分的基底构件。 一旦关闭，该装置便于气密袋的内部和真空室之间的流体连通，允许致动真空室，从而使空气从袋中排空。 舌头可以采取可移除管装置的形式，或者可以被设计成刺穿袋子。 该装置可以在排出袋子之后完全移除，或者该装置的某些部分可能保留在袋子上以便保持密封。
-
公开(公告)号：US20050261332A1
公开(公告)日：2005-11-24
申请号：US11098315
申请日：2005-04-04
申请人： Peter Distefano , Andrew Napper , Rory Curtis , Jay Luly , Jean-Francois Pons , Russell Thomas , Manuel Navia , Thomas Coulter , Jeffrey Saunders , Bard Geesaman
发明人： Peter Distefano , Andrew Napper , Rory Curtis , Jay Luly , Jean-Francois Pons , Russell Thomas , Manuel Navia , Thomas Coulter , Jeffrey Saunders , Bard Geesaman
IPC分类号： A61K31/422 , A61K31/4245 , A61K31/454 , A61K31/4745 , C07C311/32 , C07D413/02 , C07D471/02 , C07D471/10 , C07D43/02
CPC分类号： C07D471/10 , C07C311/32 , C07D401/12
摘要： Compounds of formulas (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I), (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
摘要翻译： 本文描述式（I），（II），（III）和（IV）的化合物和通过施用式（I），（II），（III）或（IV）的化合物来治疗病症的方法。 病症的实例包括肿瘤性疾病，脂肪细胞相关疾病，神经变性疾病和代谢紊乱。
-
3.发明申请Indole, azaindole and related heterocyclic N-substituted piperazine derivatives 审中-公开吲哚，氮杂吲哚和相关杂环N-取代的哌嗪衍生物公开(公告)号：US20050261296A1
公开(公告)日：2005-11-24
申请号：US11029673
申请日：2005-01-05
申请人： Kap-Sun Yeung , Michelle Farkas , John Kadow , Nicholas Meanwell , Malcolm Taylor , David Johnston , Thomas Coulter , J. Wright
发明人： Kap-Sun Yeung , Michelle Farkas , John Kadow , Nicholas Meanwell , Malcolm Taylor , David Johnston , Thomas Coulter , J. Wright
IPC分类号： A61K31/405 , A61K31/4745 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/502 , A61K31/517 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/14 , C07D471/02 , C07D471/04 , C07D487/04 , C07D491/04 , C07D43/14
CPC分类号： C07D413/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D471/04 , C07D491/04
摘要： This invention provides compounds of Formula I, including pharmaceutically accceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I have the formula wherein: Z is Q is selected from the group consisting of m is 2; A is selected from the group consisting of cinnolinyl, napthyridinyl, quinoxalinyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, azabenzofuryl, and phthalazinyl each of which may be optionally substituted with one or two groups independently selected from methyl, methoxy, hydroxy, amino and halogen; and —W— is
摘要翻译： 本发明提供具有药物和生物影响性质的式I化合物，包括其药学上可接受的盐，其药物组合物和使用方法。 这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。 式I的化合物具有下式：其中：Z为Q选自m为2; A选自噌啉基，萘啶基，喹喔啉基，吡啶基，嘧啶基，喹啉基，异喹啉基，喹唑啉基，氮杂苯并呋喃基和酞嗪基，其各自可以任选被一个或两个独立地选自甲基，甲氧基，羟基，氨基 和卤素; 和-W-是
-
公开(公告)号：US20050143426A1
公开(公告)日：2005-06-30
申请号：US11061084
申请日：2005-02-18
申请人： Michael Kelly , Shimin Xu , Ning Xi , Philip Miller , John Kincaid , Chiara Ghiron , Thomas Coulter
发明人： Michael Kelly , Shimin Xu , Ning Xi , Philip Miller , John Kincaid , Chiara Ghiron , Thomas Coulter
IPC分类号： A61K31/137 , A61K31/145 , A61K31/167 , A61K31/275 , A61K31/341 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/4045 , A61K31/417 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/426 , A61K31/4418 , A61K31/443 , A61K31/4439 , A61K31/4465 , A61K31/47 , A61K31/4965 , A61K31/50 , A61K31/505 , A61K31/52 , A61K31/5377 , A61P3/14 , A61P5/18 , A61P5/20 , A61P19/10 , C07B53/00 , C07C209/28 , C07C211/27 , C07C211/29 , C07C211/30 , C07C211/55 , C07C215/46 , C07C217/54 , C07C217/58 , C07C229/38 , C07C233/43 , C07C235/20 , C07C237/30 , C07C255/58 , C07C255/59 , C07C275/40 , C07C311/08 , C07C317/32 , C07D207/26 , C07D207/32 , C07D207/325 , C07D209/08 , C07D209/10 , C07D209/44 , C07D211/22 , C07D211/26 , C07D211/70 , C07D213/26 , C07D213/30 , C07D213/38 , C07D213/61 , C07D213/62 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/73 , C07D213/74 , C07D213/75 , C07D213/82 , C07D215/12 , C07D231/56 , C07D233/22 , C07D235/06 , C07D235/08 , C07D235/10 , C07D235/12 , C07D235/14 , C07D237/14 , C07D239/26 , C07D239/34 , C07D239/42 , C07D239/47 , C07D241/12 , C07D241/42 , C07D249/18 , C07D261/08 , C07D263/32 , C07D263/56 , C07D271/06 , C07D271/10 , C07D271/12 , C07D277/24 , C07D277/28 , C07D277/40 , C07D277/42 , C07D277/66 , C07D277/78 , C07D285/00 , C07D285/01 , C07D295/096 , C07D295/135 , C07D295/185 , C07D295/26 , C07D307/42 , C07D307/52 , C07D307/68 , C07D317/46 , C07D317/54 , C07D317/58 , C07D319/18 , C07D321/10 , C07D333/16 , C07D333/20 , C07D333/56 , C07D401/12 , C07D405/12 , C07D471/04 , C07D473/00 , C07D487/04 , A61K31/138 , A61K31/44
CPC分类号： C07C233/36 , C07C211/27 , C07C211/29 , C07C211/30 , C07C211/55 , C07C215/46 , C07C217/54 , C07C217/58 , C07C229/38 , C07C233/43 , C07C233/46 , C07C235/20 , C07C237/30 , C07C255/58 , C07C255/59 , C07C275/40 , C07C311/08 , C07C317/32 , C07C2601/02 , C07D207/26 , C07D207/27 , C07D207/325 , C07D209/08 , C07D209/10 , C07D209/44 , C07D211/22 , C07D211/70 , C07D213/26 , C07D213/30 , C07D213/38 , C07D213/61 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/73 , C07D213/75 , C07D213/82 , C07D215/12 , C07D215/14 , C07D231/56 , C07D233/22 , C07D235/06 , C07D235/10 , C07D235/12 , C07D237/08 , C07D237/14 , C07D239/26 , C07D239/34 , C07D239/42 , C07D241/12 , C07D241/42 , C07D249/18 , C07D261/08 , C07D263/32 , C07D263/56 , C07D271/06 , C07D271/08 , C07D271/10 , C07D271/12 , C07D277/24 , C07D277/28 , C07D277/40 , C07D277/42 , C07D277/66 , C07D285/01 , C07D295/096 , C07D295/135 , C07D295/185 , C07D295/26 , C07D307/42 , C07D307/52 , C07D307/68 , C07D317/46 , C07D317/54 , C07D319/18 , C07D321/10 , C07D333/16 , C07D333/20 , C07D333/56 , C07D401/12 , C07D405/12 , C07D471/04 , C07D487/04
摘要： The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
-
公开(公告)号：US20050075364A1
公开(公告)日：2005-04-07
申请号：US10871931
申请日：2004-06-18
申请人： Kap-Sun Yeung , Michelle Farkas , John Kadow , Nicholas Meanwell , Malcolm Taylor , David Johnston , Thomas Coulter , J. J. Wright
发明人： Kap-Sun Yeung , Michelle Farkas , John Kadow , Nicholas Meanwell , Malcolm Taylor , David Johnston , Thomas Coulter , J. J. Wright
IPC分类号： A61K31/405 , A61K31/4745 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/502 , A61K31/517 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/14 , C07D471/02 , C07D471/04 , C07D487/04 , C07D491/04
CPC分类号： C07D413/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D471/04 , C07D491/04
摘要： This invention provides compounds of Formula I, including pharmaceutically accceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I have the formula wherein: Z is Q is selected from the group consisting of m is 2; A is selected from the group consisting of cinnolinyl, napthyridinyl, quinoxalinyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, azabenzofuryl, and phthalazinyl each of which may be optionally substituted with one or two groups independently selected from methyl, methoxy, hydroxy, amino and halogen; and —W— is
-
公开(公告)号：US20110152232A1
公开(公告)日：2011-06-23
申请号：US12912266
申请日：2010-10-26
IPC分类号： A61K31/4245 , C07D271/06 , C07D249/08 , C07D413/04 , C07D405/04 , C07D403/04 , C07D417/04 , C07D409/04 , C07D471/04 , C07D401/04 , A61K31/4196 , A61K31/4439 , A61K31/428 , A61K31/427 , A61K31/437 , A61K31/538 , A61P3/04 , A61P3/00 , A61P3/10
CPC分类号： C07D249/08 , C07D271/06 , C07D401/04
摘要： Compounds that modulate GHS-R are described, for examples compounds formula (I)
摘要翻译： 描述了调节GHS-R的化合物，例如化合物式（I）
-
公开(公告)号：US07829589B2
公开(公告)日：2010-11-09
申请号：US11564815
申请日：2006-11-29
IPC分类号： A61K31/4196 , C07D249/08
CPC分类号： C07D249/08 , C07D271/06 , C07D401/04
摘要： Compounds that modulate GHS-R are described, for examples compounds formula (I)
摘要翻译： 描述了调节GHS-R的化合物，例如化合物式（I）
-
公开(公告)号：US20060205697A1
公开(公告)日：2006-09-14
申请号：US11272019
申请日：2005-11-14
申请人： Gary Robinson , Carl Wild , Mark Ashton , Russell Thomas , Christian Montalbetti , Thomas Coulter , Filippo Magaraci , Robert Townsend , Theodore Nitz
发明人： Gary Robinson , Carl Wild , Mark Ashton , Russell Thomas , Christian Montalbetti , Thomas Coulter , Filippo Magaraci , Robert Townsend , Theodore Nitz
摘要： The present invention relates to novel synthetic derivatives of betulin and the use of such derivatives as pharmaceuticals. The present invention is directed to novel compounds of Formula I: or a pharmaceutically acceptable salt or prodrug thereof.
摘要翻译： 本发明涉及新颖的桦木素合成衍生物和药物衍生物的用途。 本发明涉及新的式I化合物：或其药学上可接受的盐或前药。
-
9.发明申请Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer 审中-公开二苯基吲哚-2-酮化合物及其在治疗癌症中的应用公开(公告)号：US20070299102A1
公开(公告)日：2007-12-27
申请号：US10599121
申请日：2005-04-08
申请人： Jakob Felding , Hans Pedersen , Christian Krog-Jensen , Morten Praestegaard , Steven Butcher , Viggo Linde , Thomas Coulter , Christian Montalbetti , Mohammed Uddin , Serge Reignier
发明人： Jakob Felding , Hans Pedersen , Christian Krog-Jensen , Morten Praestegaard , Steven Butcher , Viggo Linde , Thomas Coulter , Christian Montalbetti , Mohammed Uddin , Serge Reignier
IPC分类号： A61K31/40 , A61K31/44 , A61P43/00 , C07D209/36 , C07D221/02
CPC分类号： A61K31/404 , A61K31/407 , A61K31/4188 , A61K31/429 , A61K31/437 , A61K31/4439 , A61K31/4745 , A61K31/496 , A61K31/5025 , A61K31/5377
摘要： The present invention relates to substituted 3,3-diphenyl-1,3-dihydro-indol-2-one compounds, and the use of such compounds for the preparation of a medicament for the treatment of cancer in a mammal. It is postulated that treatment of cancers is achieved in which inhibition of protein synthesis and/or inhibition of activation of the mTOR pathway is an effective method for reducing cell growth. Examples of such cancers are breast cancer, renal cancer, multiple myeloma, leukemia, glia blastoma, rhabdomyosarcoma, prostate, soft tissue sarcoma, colorectal sarcoma, gastric carcinoma, head and neck squamous cell carcinoma, uterine, cervical, melanoma, lymphoma, and pancreatic cancer. A particular subclass of compounds are represented by the formula (II) wherein at least one of X1 and X2 is a heteroatom substituent, e.g. 6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one.
摘要翻译： 本发明涉及取代的3,3-二苯基-1,3-二氢 - 吲哚-2-酮化合物，以及这些化合物在哺乳动物中制备用于治疗癌症的药物的用途。 假定癌症的治疗实现了其中抑制蛋白质合成和/或抑制mTOR途径的活化是减少细胞生长的有效方法。 这样的癌症的例子是乳腺癌，肾癌，多发性骨髓瘤，白血病，胶质母细胞瘤，横纹肌肉瘤，前列腺，软组织肉瘤，结肠直肠肉瘤，胃癌，头颈鳞状细胞癌，子宫颈，宫颈癌，黑素瘤，淋巴瘤和胰腺癌 癌症。 化合物的特定亚类由式（II）表示，其中X 1和X 2中的至少一个是杂原子取代基，例如杂原子取代基。 6-氯-3,3-双 - （4-羟基 - 苯基）-7-甲基-1,3-二氢 - 吲哚-2-酮。
-
公开(公告)号：US20070270473A1
公开(公告)日：2007-11-22
申请号：US11564815
申请日：2006-11-29
IPC分类号： A61K31/44 , A61K31/40 , C07D211/82 , C07D207/30
CPC分类号： C07D249/08 , C07D271/06 , C07D401/04
摘要： Compounds that modulate GHS-R are described, for examples compounds formula (I)
摘要翻译： 描述了调节GHS-R的化合物，例如化合物式（I）
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.033 秒)
